Neuroblastoma is an embryonic malignancy that arises out of the neural crest cells of the sympathetic nervous system. It is the most common childhood tumor known for its spontaneous regression via the process of differentiation. The induction of differentiation using small molecules such as retinoic acid is one of the therapeutic strategies to treat the residual disease. In this study, we have reported the effect of kaempferol (KFL) in inducing differentiation of neuroblastoma cells in vitro. Treatment of neuroblastoma cells with KFL reduced the proliferation and enhanced apoptosis along with the induction of neuritogenesis. Analysis of the expression of neuron-specific markers such as b-III tubulin, neuron-specific enolase, and N-myc downregulated gene 1 revealed the process of differentiation accompanying KFL-induced apoptosis. Further analysis to understand the molecular mechanism of action showed that the effect of KFL is mediated by the activation of the endoribonuclease activity of inositol-requiring enzyme 1 alpha (IRE1a), an endoplasmic reticulum-resident transmembrane protein. In silico docking analysis and biochemical assays using recombinant human IRE1a confirm the binding of KFL to the ATP-binding site of IRE1a, which thereby activates IRE1a ribonuclease activity. Treatment of cells with the small molecule STF083010, which specifically targets and inhibits the endoribonuclease activity of IRE1a, showed reduced expression of neuron-specific markers and curtailed neuritogenesis. The knockdown of IRE1a using plasmid-based shRNA lentiviral particles also showed diminished changes in the morphology of the cells upon KFL treatment. Thus, our study suggests that KFL induces differentiation of neuroblastoma cells via the IRE1a -XBP1 pathway.
Introduction
Neuroblastoma, the most common solid extra cranial malignant tumor of infants originates from the precursor cells that derived from the neural crest tissues [1] .
These cells can get differentiated into any other cell types of neural origin [2] . The clinical representation of the disease varies drastically from a mass with no symptoms to a primary tumor causing critical illness with tumor disseminates into the neck, thorax, abdomen, or pelvis and stands as the most commonly diagnosed tumor in early childhood [3] . The heterogeneity of neuroblastoma tumors makes intense chemoradiotherapy as a therapeutic intervention. Therefore, for minimizing the effect of chemoradiotherapy, alternative therapeutic strategies targeting crucial proteins involved in the tumor progression are needed. The derivatives of retinoic acid (RA) are widely used clinically after cytotoxic therapy as differentiation inducing agents for controlling minimal residual disease in highrisk neuroblastoma patients [4] .
Retinoic acid, a derivative of vitamin A has been shown to promote differentiation of embryonic, neural, and mesenchymal stem cells [5] . All-trans RA (ATRA), 9-cis RA, and 13-cis RA are the wellknown RA isomers that have been shown to induce differentiation and used in the treatment of neuroblastoma [6] . Resistance to RA therapy is commonly observed in vitro as well as clinically, due to the mutations in RA receptor (RAR) gene or RAR receptor [7] . In addition, trichostatin A, kenpaullone, and SB-216763 has also been reported to induce neuritogenesis in vitro [8, 9] . Recent studies reported alectinib (Anaplastic Lymphoma Kinase inhibitor) and YK-4-279 (mitosis disruptor) as promising candidates for neuroblastoma treatment by emphasizing the lack of effective therapies at present in clinics [10, 11] . Inositol-requiring enzyme 1 alpha (IRE1a) is an endoplasmic reticulum (ER)-resident protein involved in the unfolded protein response (UPR) pathway. It has a luminal N-terminal domain inside ER lumen and two functional enzymatic cytoplasmic domains having kinase and endoribonuclease activities. The activation of IRE1a is via the accumulation of misfolded proteins or by other physiological stimuli not limiting to lipid perturbation, viral infection, or immune response [12] which leads to the initiation of its kinase or endoribonuclease activity. The kinase activity is known for the recruitment of TRAF2 protein and activation of c-Jun N-terminal kinase (JNK)-mediated signaling cascade, thereby driving cells toward an apoptotic response [13] . The ribonuclease activity of IRE1a can cleave multiple RNA substrates involved in diverse cell response pathways with X-box binding protein 1 (Xbp1) mRNA being the major substrate. A spliced form of Xbp1 mRNA gets translated into an active transcription factor XBP1s that is involved in the transcription of variety of genes [14] . The mouse embryos lacking IRE1a died after 11.5-14.5 days post-coitum emphasizing the role of IRE1a in the developmental stages of the organism [15] . Moreover, the IRE1a-XBP1 pathway of gene activation is known to be a critical factor involved in the differentiation of plasma cells, osteoblasts, and adipocytes [16] [17] [18] .
Kaempferol (KFL) is a phytoestrogen that belongs to the class of flavonoids and is known to exhibit antioxidant, anti-inflammatory, and anticancer activities [19] . In our attempt toward identifying an inhibitor against ER stress-induced cell death, we found KFL to rescue mammalian cells from apoptosis induced by multiple cell death inducers by acting as an allosteric inhibitor for executioner caspases [20] . While performing the experiments we observed changes in morphology of IMR32 cells, a human neuroblastoma cell line with neurite like outgrowths, upon prolong incubation in the presence of KFL.
In this study, we have investigated the effect of KFL on neuroblastoma cell lines, IMR32 and Neuro2a. Observations made in our experiments suggest that KFL-mediated differentiation of neuroblastoma cells happens via the activation of IRE1a endoribonuclease activity. Since KFL is a dietary polyphenol and cohort studies had been performed for understanding its effect on various other cancers [21] , it could also be explored for its effect on neuroblastoma in preclinical and clinical trials.
Results

Kaempferol induces neuroblastoma differentiation and decreases cell viability
To understand the effect of KFL on neuroblastoma cells, we employed IMR32 and Neuro2a cell lines, well-established in vitro models that have been used widely for understanding neuroblastoma differentiation. IMR32 and Neuro2a cells were incubated in the presence of KFL (50 lM) for 4 days; cells cultured in the presence of ATRA (25 lM) that served as a positive control. After 48 h of incubation, we observed morphological changes including neurite outgrowth associated with decreased proliferation and viability. To confirm whether the neurite outgrowth is due to cellular differentiation, we performed immunocytochemistry to analyze the expression of b-III tubulin, a neuronal differentiation marker. The significant increase in the expression level of b-III tubulin in the KFL-and ATRA-treated cells compared to the controls confirmed the neurite outgrowth to be due to the cellular differentiation (Fig. 1A) . A further assessment on the viability of the cells using 3 -[4,5 dimethylthiazol -2 -yl] -2,5 -diphenyltetrazolium bromide (MTT) assay and trypan blue dye exclusion assay revealed that KFL decreased the viability of (24, 48, 72, 96 h ) and y-axis shows the relative cell survival compared to DMSO-treated control cells. The assay was performed in triplicate and the graph represents the average AE SEM from three independent experiments performed. (**P < 0.01; ***P < 0.001; two-way ANOVA). (C) Trypan blue dye exclusion assay was performed to analyze the effect of KFL and ATRA on the proliferation of IMR32 cells. In a 24-well plate, 50 9 10 3 were seeded on day 0 and treated with respective concentrations of KFL or ATRA. DMSO-treated cells served as control. Cells were collected on day 2, day 3, and day 4 and stained using trypan blue dye, and then live cells were counted manually using haemocytometer. Data represented as average AE SEM of counting obtained from three independent experiments performed in triplicates (***P < 0.001; two-way ANOVA). Dashed line represents the seeding density of 50 9 10 3 cells on day 0. (D) IMR32 cells (seeding density at 10 9 10 4 cells per 60 mm dish) treated with ATRA and KFL were viewed under phase contrast microscope equipped with color camera at 48, 72, and 96 h time points. Percent DMSO-treated cells were represented as control. Images showed a reduction in confluence and change in morphology in KFL 50 lM and ATRA 25 lM treated cells compared to the control cells. Representative image of experiments performed for three times. Scale bars = 100 lm. (E) Change in the morphology of IMR32 and Neuro2a cells upon KFL or ATRA treatment for 96 h was captured using phase contrast microscope equipped with monochrome camera. An increase in the number of cells bearing neurite like extensions upon treatment was observed. Representative image of experiments performed for three times. Scale bars = 67 lm. (F) Cells bearing two or more neurites in IMR32 and Neuro2a cells treated with KFL (50 lM) or ATRA (25 lM) for 96 h were counted manually. The y-axis in the graph represents the percentage of cells bearing two or more neurites compared to the control cells treated with DMSO. The average AE SEM from independent counting performed in 10 random focuses is shown (*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA).
both IMR32-and Neuro2a-treated cells (Fig. 1B,C,  D ). An additional quantitation of the number of cells bearing two or more neurites indicated that an incubation period of 4 days is sufficient for KFL to effectively induce a significant change in the morphology (Fig. 1E,F) , while in ATRA-treated cells there were lesser morphological changes in terms of neurite extensions when compared to KFL-treated cells. ATRA had been shown to require 10-14 days for a significant change in morphology [22] , while KFL induced these changes in 4 days of treatment. Complementarily, we observed an increase in the mRNA and protein levels of certain neuron-specific marker genes like synaptophysin (SYP), neuron-specific enolase (NSE), and N-myc downregulated gene 1 (NDRG1; Fig. 2A,B) . Although the mRNA transcripts of NSE and NDRG1 in ATRA-treated condition did not show significant upregulation, the protein levels were upregulated during day 3 and day 4 of differentiation. The expression of N-myc, at mRNA level, was downregulated in KFL-treated conditions, while it was significantly increased in ATRA-treated conditions ( Fig. 2A) . In contrast, the downregulation of Nmyc observed at the mRNA level was not exactly the same as observed at the protein level as there was no such drastic reduction in N-myc protein levels (Fig. 2B) . The reason for this could be the accumulation of N-myc protein due to protein stabilization rather than transcription of the gene [23] . Moreover, the increase in the expression of N-myc protein is shown to be a required criterion for the onset of differentiation [24] . However, we observed an increase in NDRG1 expression levels with a decrease in the expression level of N-myc protein between day 2 and day 4 (Fig. 2B) ; a phenomenon reported to occur during neuroblastoma differentiation [25] . Moreover, we analyzed the expression of apoptotic and proliferative marker genes upon KFL treatment in IMR32 cells (Fig. 2C) . KFL treatment showed significant upregulation of apoptotic marker gene death receptor 5 (DR5) and tumor necrosis factor receptor type 1 (TNFR1). The upregulation of DR5 upon KFL treatment had been reported in other cancer cells as a contributing factor for KFL induced cell death in cancer cells [26, 27] . The significant upregulation of antiproliferative gene p21 observed in our study supports the cease in the proliferation of IMR32 cells after KFL treatment. A downregulation of Cyclin D1 expression was observed in both KFL and ATRA treatment (Fig. 2C) . Altogether, our data suggest that KFL promotes differentiation and cell death in neuroblastoma cells.
Kaempferol-induced neuroblastoma differentiation is independent of the estrogen receptor signaling
It has been previously reported that KFL as a phytoestrogen (estrogen receptor agonist) suppresses the proliferation of breast cancer cells and promotes apoptosis and the use of an antagonist against estrogen receptors had shown to reverse the biological activity of KFL [28] . Since ESRb signaling has been shown to be essential for KFL-mediated biological responses [29] , we examined the expression of ESRa and ESRb in IMR32 cells. In our study, we observed that KFL substantially induces the expression of estrogen receptor b (ESRb) compared to the estrogen receptor a (ESRa) both at mRNA level and at protein level in IMR32 cells (Fig. 3A,B (Fig. 3D) . Collectively, these findings suggest that KFL-induced neuroblastoma differentiation and cell death is not mediated by ESRb signaling.
Kaempferol modulates the expression of IRE1a
Endoplasmic reticulum stress is known to be associated with cancer cell differentiation [31] and KFL has been known to induce ER stress in certain cancer cell lines [32, 33] . These research findings prompted us to check the expression level of ER stress marker genes such as BiP, PERK, IRE1a, and ATF6 in KFL-treated IMR32 cells. The results presented in Fig. 4A show that KFL significantly increased the expression of IRE1a, while not having a significant effect on other ER stress marker genes (Fig. 4A ). IRE1a is an ER transmembrane sensor of UPR pathway with both kinase and endoribonuclease activity. During ER stress, IRE1a activation initiates the splicing of XBP-1 mRNA which in turn gets translated into XBP1s protein that is involved in transcription of a diverse set of genes including genes involved in the UPR pathway [14] . Previous studies have reported the involvement of IRE1a-XBP1 pathway in the differentiation of plasma cells [16] , osteoclasts [17] , and adipocytes [18] , in addition to the UPR pathway. This led us to hypothesize whether KFL might induce the neuroblastoma differentiation by modulating the IRE1a-XBP1 pathway. We then performed protein analysis of IRE1a for KFL-treated cells and compared it with brefeldin A (BFA; a known inducer of ER stress)-treated cells.
Our results indicated that KFL increased the expression of IRE1a but not BiP at protein level. BiP is a molecular chaperone and increase in the BiP levels is considered a hallmark of the ER stress process. In contrast, BFA treatment upregulated the expression levels of IRE1a as well as BiP proteins indicating the onset of strong ER stress response (Fig. 4B ). We have previously showed the bioactivity of KFL in ameliorating ER stress-induced cell death with a reduction in the expression level of ER stress markers in IMR32 The mRNA expression of DR5, TNFR1, p21, and Cyclin D1 were quantified using qRT-PCR with 18s rRNA as internal control. DMSO-treated cells were used as control for normalization. Graphs are represented as the average AE SEM from three independent experiments. (*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA).
cells upon pretreatment with KFL [20] . Our present study showed that KFL increased the expression of IRE1a without activating ER stress in IMR32 cells.
Activation of IRE1a endoribonuclease activity by kaempferol
Quercetin, a flavonoid, has been reported to bind to the Q-site in human-yeast chimeric IRE1 and activates endoribonuclease activity to enhance the cleavage of XBP1 mRNA [34] . KFL also belongs to the flavonoid class of phytocompounds. Considering this, we employed computational docking studies using Autodock to check if KFL binds to human IRE1a molecule. Blind docking was performed by selecting the complete surface of the protein molecule. The result showed the KFL's binding affinity toward the kinase pocket of IRE1a (Fig. 4C ). The binding of KFL was compared to bound states of indigenous activator of IRE1a, ADP, and APY29 (known IRE1 kinase inhibitor and endoribonuclease activator; Fig. 4D ). The bound state of ADP in the IRE1a nucleotide binding site is known to activate the endoribonuclease activity of the molecule [35] . The docked poses analyzed for amino acid residues occupying the bound state of KFL showed that the binding of KFL to the kinase pocket of the molecule share the similar amino acid residues for interactions as of ADP and APY29 (Fig. 4D ). The interactions of KFL with Glu 643, Cys 645, and His 692 residues of human IRE1a had been shown for kinase activity inhibition by staurosporine (STS), a pan kinase inhibitor [36] . APY29 has been known to interact with amino acid residues of kinase domain to activate the endoribonuclease activity of IRE1a [37] . Moreover, the interaction with Cys 645 at the kinase cleft has been reported for APY29 to Results show no effect on the percent viability of cells pretreated with PHTPP (25 lM) in presence of KFL. The graphs represent average AE SEM from three independent experiments performed in triplicates (*P < 0.05; **P < 0.01; one-way ANOVA). , and 12 h time points after treatment. The mRNA expression levels of IRE1a, BiP, PERK, and ATF6 upon KFL treatment were quantified using qRT-PCR. 18s rRNA was used as internal control and gene expression in DMSO-treated cells was used for normalization. Graphs represent the average AE SEM from three independent experiments (*P < 0.05; ***P < 0.001; two-way ANOVA). (B) Proteins extracted from IMR32 cells treated with KFL (50 lM) or BFA (1 lgÁmL À1 ) at 3, 6, and 12 h time points were analyzed using western blotting activate the IRE1a endoribonuclease activity [38] . The conformation of DFG (Aspartic acid-PhenylalanineGlycine) motif of kinase domain in IRE1a with an activator for endoribonuclease activity should be in DFG-in conformation rather than DFG-out [38] . The ADP bound crystal structure of IRE1a (PDB ID: 3P23), with DFG-in motif showing favorable binding affinity for docking with KFL suggests its ability to modulate the IRE1a endoribonuclease activity. Moreover, docked pose of KFL falls into the same pocket where ADP and APY29 are known to interact with the kinase domain of IRE1a (Fig. 4E) . Collectively, docking analysis showed that KFL binds to the kinase domain of IRE1a and could activate the endoribonuclease activity.
To confirm the docking results further, ADP-Glo kinase assay (Promega, Madison, WI, USA) was performed using recombinant kinase active human IRE1a. Incubation of KFL with IRE1a showed a dose-dependent decrease in the kinase activity of IRE1a (Fig. 4F) , confirming its binding to the kinase domain of the protein and thereby inhibiting IRE1a's kinase activity. The kinase inhibition assay performed by increasing the concentration of the substrate ATP from 10 to 100 lM, suggested a noncompetitive mode of inhibition favored by KFL (Fig. 4G) , which again correlates with the previously reported weak binding of quercetin [34] to the nucleotide binding site of human-yeast chimeric IRE1 protein.
IRE1a knockdown reduces neuroblastoma differentiation
To further confirm the role of IRE1a-XBP1 pathway in neuroblastoma differentiation, we established stable IRE1a knockdown clones of IMR32 cells using lentiviral particles containing IRE1a shRNA (four targetspecific constructs that encodes 19-25 nucleotide shRNA). Successful knock down of IRE1a at mRNA and protein level was confirmed by qRT-PCR and immunoblotting, respectively (Fig. 5A,B) . The functional involvement of IRE1a in neuroblastoma differentiation is confirmed, when neither KFL or APY29 treatment triggered b-III tubulin expression in IRE1a knockdown IMR32 cells (Fig. 5C) . Additionally, to compare the expression of neuronal differentiation markers (NDRG1 and NSE) between IRE1a knockdown cells and control shRNA transduced cells, we performed immunoblotting analysis. We observed a decrease in the expression level of these markers in IRE1a knockdown cells when compared to the control shRNA transduced cells (Fig. 5D) . Also, we noticed a reduction in the XBP1s protein level in IRE1a shRNA-treated conditions on day 4, with a reduced level of differentiation observed. To confirm the endoribonuclease activity in inducing the differentiation of neuroblastoma cells, we inactivated the endoribonuclease activity of IRE1a by using STF083010, a small molecule inhibitor. STF083010 is a specific inhibitor which binds to the endoribonuclease domain of IRE1 and inhibits the cleavage of XBP1 mRNA (Fig. 5E ), while the kinase activity is left intact [39] . The extent of differentiation repression in IRE1a knockdown cells, in the presence of KFL or APY29 was further enhanced by the addition of STF083010 (the IRE1 endoribonuclease inhibitor), to these cells (Fig. 5F ). The number of cells with two or more neurites was significantly less in IRE1a knockdown cells that are treated with either KFL or APY29, and this reduction in neurite growth was further decreased upon pretreatment with STF083010 (Fig. 5G) . These results validate the role of IRE1a's endoribonuclease activity in KFL induced neuroblastoma differentiation.
XBP1s drives differentiation of neuroblastoma cells
Activated IRE1a splices the XBP1 mRNA, which then gets translated into an active transcription factor that regulates diverse set of genes involved in the regulation of various cellular processes including genes related to ER stress, differentiation, cell cycle arrest, and immune response. The ratio of spliced to unspliced form of XBP1 mRNA corresponds to the extent of IRE1a activation. Small molecule modulators binding to the nucleotide binding site of IRE1a can induce the endoribonuclease activity in the absence of ER stress [40] .
Therefore, we decided to check the expression level of spliced XBP1 mRNA by qRT-PCR. IMR32 cells were treated with KFL or BFA. While comparing the mRNA expression of XBP1 unspliced to spliced form, we observed an enhanced XBP1 spliced mRNA levels upon KFL treatment. The increase in the expression of XBP1 (unspliced) mRNA correlates with the enhanced expression of ATF6 [41] and this was not the case for BFA-treated cells as they displayed a decrease in the expression level of XBP1 unspliced form (Fig. 6A) . To confirm that XBP1s protein is transcriptionally active, we analyzed its downstream targets such as SEC63, protein disulphide isomerase A 2 (PDIA2), PDIA3, DnaJ homolog subfamily C 3 (DNAJC3), endoplasmic reticulum DnaJ 4 and 5 (ERDJ4 and ERDJ5) mRNA level by qRT-PCR, the regulation of these targets by the transcription factor XBP1s was validated before [42] . These downstream targets of XBP1s transcription factor were not selected randomly; they have certain roles in the events pertaining to cellular differentiation. High SEC63 expression has been shown to have an involvement in apoptosis and reduced proliferation in hepatic tumors [43] ; ERDJ4 has been shown to have a crucial role in B cell differentiation in the event of hematopoiesis [44] . Besides, DNAJC3 levels are known to increase during plasma cells differentiation [45] ; the expression of PDIA3 and DNAJC3 was shown to be upregulated during T-helper cell differentiation and treatment with IRE1a's endoribonuclease activity specific inhibitor 4l8c downregulated their expression via inhibiting XBP1 mRNA splicing [46] . Our results suggested that expression of all these genes increased in KFL-treated conditions, and get reversed by pretreatment with STF083010 (Fig. 6B) . These results confirm that KFL activates XBP1s transcriptional activity by activating the endoribonuclease activity of IRE1a and STF083010 blocks the transcriptional activity induced by KFL by inhibiting XBP1 mRNA cleavage. Furthermore, we proceeded to check whether APY29, an activator of IRE1a endoribonuclease activity could induce the differentiation of IMR32 cells similar to KFL. Western blot analysis of APY29-treated cell lysates showed an increase in the expression of neuronal differentiation markers similar to that of KFL-treated conditions (Fig. 6C) . STF083010 (50 lM) did not have cytotoxic effect in IMR32 cells; pretreatment with STF083010 followed by KFL treatment also did not modulate cell death (Fig. 6E) suggesting that cell death induction by KFL is independent of IRE1a-XBP1 pathway. However, immunocytochemistry analysis for the expression of b-III tubulin showed reduced differentiation upon STF083010 pretreatment, in both KFL-and APY29-treated conditions (Fig. 6D ). In addition, there was a reduced change in morphology and a decrease in the number of cells bearing neurites with STF083010 pretreatment in the presence of KFL or APY29 (Fig. 6F,  G) . The induction of differentiation by APY29 observed in Neuro2a cells was similar to KFL-treated conditions. There was a marked increase in the b-III tubulin expression and SYP vesicles observed in immunocytochemistry experiments undertaken in Neuro2a cells (Fig. 7A,B) . Taken together, these results suggest that KFL activates the IRE1a-XBP1 branch pathway to induce the neuroblastoma differentiation. In addition, we analyzed if IRE1a-XBP1 pathway is involved in inducing neuroblastoma differentiation by other agents like CDDO and ATRA [47] . However, we found that preincubation of cells with STF083010 did not inhibit differentiation induced by CDDO or ATRA (Fig. 8A,B) suggesting that IRE1a activation is not the only pathway involved in neuroblastoma differentiation. Altogether, these results suggest that STF083010 inhibits differentiation but not cell death induced by KFL and APY29. Therefore, the activation of endoribonuclease activity of IRE1a followed by the XBP1 mRNA splicing holds a crucial role in ) and total RNA was isolated at 3, 6, and 12 h time points. Graphs representing the spliced and unspliced form of xbp1 mRNA present upon KFL and BFA treatment. Ratio represented to point out that KFL-treated cells maintains high expression levels of xbp1 spliced and unspliced form. The graph represents the average AE SEM from three independent experiments (*P < 0.05; **P < 0.01; ***P < 0.001; two-way ANOVA). (B) IMR32 cells were treated with KFL in the presence and absence of STF083010 (50 lM). Total RNA was isolated after 12 h of treatment and gene expression studies on six downstream transcriptional targets (SEC63, ERDJ4, ERDJ5, DNAJC3, PDIA2, and PDIA3) of XBP1s were performed using qRT-PCR. 18s rRNA was used as internal control and gene expression was normalized with respect to the gene expression in DMSO-treated control cells. The average AE SEM experiments performed in duplicates (n = 3). * represents comparison between control and KFL-treated cells; # represents comparison between KFL-treated cells with STF083010-treated cells (*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA). inducing the differentiation of neuroblastoma cells. This could be the reason for the morphological changes and neurite outgrowths observed earlier in other neuroblastoma cell lines upon treatment with flavonoids [48, 49] .
Discussion
Although several studies have been done in improving the prognosis of high-risk neuroblastoma with differentiation therapies, the survival rate of patients remains considerably poor [50] . The implementation of chemotherapeutic approaches with synthetic molecules also adds up to the detrimental effects on the patients. Therefore, an enhanced understanding of differentiation pathways and novel therapeutic approaches are needed. An approach using dietary compounds or plant metabolites could be a better alternative for reducing the damaging effects of synthetic drugs. RA and its derivatives are well explored for their effects in inducing differentiation of neuroblastoma cells in clinical therapies. Other than RA, there are reports on the activity of 17b-estradiol in enhancing the neuritogenesis in pheochromocytoma cells, in vitro [51] . Flavonoids, being known for their anticancer activity, mimic estrogen in physiological systems, while some of them have been reported to induce neuritogenesis in neuroblastoma cells in vitro [48, 49] . KFL had been reported before for its anticancer activity via multiple cellular pathways which include upregulation of DR5 receptor expression via estrogen receptor expression and suppression of signal-regulated kinases [28] .
The role of IRE1a in differentiation of multiple cell types shows its involvement in deciding the fate of cells. XBP1 mRNA, the major substrate for the IRE1a endoribonuclease activity, has been shown to transcribe genes that are involved in multiple cellular processes, including genes involved in the differentiation of numerous cell types. The role of quercetin, a flavonoid, in activating the endoribonuclease activity of IRE1a gave a hint to explore the anticancer activity of KFL in the viewpoint of the role of IRE1a-XBP1 pathway in the differentiation of neuroblastoma cells [34] . Moreover, the inactivation of IRE1a endoribonuclease activity and the hypomorphic expression of XBP1 in intestinal stem cells has been shown to be the reason for intestinal tumorigenesis [52] .
The difference in the gene expression pattern between KFL-and ATRA-treated conditions shows that they both could activate different pathways to induce neuroblastoma differentiation. CDDO, a synthetic triterpenoid has been shown to induce differentiation of IMR32 cells via PPARɣ signaling pathway while ATRA has its effect via CREB dependent pathways [47] . The difference between the mRNA and protein expression of NSE observed in ATRA-treated condition was observed in other studies as well. The differentiation of SK-N-DZ cells by overexpression of the aryl hydrocarbon receptor showed no change in the regulation of NSE at transcript levels [53] . These data suggest that the transcripts of neuronal markers might be regulated via post-transcriptional regulatory mechanisms. Aside from the activation of IRE1a -XPB1 pathway, critical role of activation of other signaling pathways such as cMAP and p38 mitogenassociated protein kinase (MAPK) pathway [54] , JNK-MAPK pathway, and PPARɣ signaling pathway [47] have been reported to have a critical role in inducing the differentiation of neuroblastoma cells.
In summary, the current study demonstrated the involvement of IRE1a in the differentiation of neuroblastoma cells. Modulation of IRE1a in neuroblastoma cells by KFL, or by any specific modulator entitled for activating the endoribonuclease activity of IRE1a, showed enhanced cell death, proliferation-repression coupled to differentiation, with increase in expression of neuronal markers, all of which are expected outcomes of neuroblastoma therapies. The results presented herein demonstrate that KFL induces differentiation and cell death of neuroblastoma cells. Also, present study suggests a new therapeutic approach via modulation of IRE1a for the treatment of neuroblastoma.
Materials and methods
Cell culture and reagents 
Cell proliferation assay
For trypan blue dye exclusion assay, 0. 
Differentiation experiments
For differentiation experiments, neuroblastoma cell lines were seeded at a density of 3 9 10 5 cells in 60 mm dish and treated with 50 lM of KFL. Induction was given once for a continuous time of 96 h without any replacement of media. ATRA at a concentration of 25 lM was used as a positive control to compare the morphological changes; images were taken using phase contrast microscope at specified time points.
Stable lentiviral transductions
The IRE1a (sc-40705-V) shRNA lentiviral particles purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) contain expression constructs encoding target-specific shRNA designed to specifically knock down human IRE1a gene expression. Scrambled shRNA contained lentiviral particles (sc-108080; Santa Cruz Biotechnology) that do not lead to specific degradation of any cellular mRNA and was used as negative control. Lentiviral transduction was performed in the presence of polybrene (5 lgÁmL
À1
; Sigma-Aldrich, St. Louis, MO, USA), and stable transductants were generated via selection with puromycin (1 lgÁmL À1 ; Sigma-Aldrich) according to the manufacturer's instructions.
Immunocytochemistry and microscopy
Immunocytochemistry was carried out as described in the Cell signaling Technology (CST) guide. Briefly, 2. 
Gene expression analysis
Total RNA isolation was performed using RNA isoplus (Takara, New Delhi, India). RNA quantification was performed and 2 lg of total RNA was used for cDNA conversion using Primescript RT reagent kit (Takara).
Quantitative-PCR (qRT-PCR) was performed using SYBR green reagent (Takara) using Applied Biosystems (Waltham, MA, USA) Quant studio 3 real-time PCR Table 1 . List of primers used in this study.
ATGTTCGTGGCCTCTAAGATGA CAGGTTCCACTTGAGCTTGTTC machine. Human 18s rRNA was used as an internal control for normalizing the gene expression. The fold-induction of mRNA levels was calculated by 2 ÀDDCT method. The list of primers used in this study is tabulated (Table 1) .
Immunoblotting
Immunoblotting was carried out as described earlier by Ravanan et al. [55] . In brief, cells were plated in 60 mm dishes at the density of 1. 
Methylene blue staining and neurite counting
Cells were seeded in 35 mm dish at a density of 1.5 9 10 5 cells and differentiation was induced with KFL (50 lM) or APY29 (250 nM). Wherever STF083010 (50 lM) is used as inhibitor, cells were pretreated with STF083010 for 90 min and then treated with the above mentioned test compounds. After 96 h of incubation, cells were fixed using 4% formaldehyde for 15 min and stained using 0.2% methylene blue solution in methanol for 30 min. After repeated washes for unbound stain removal, images were taken using monochrome phase contrast camera of EVOS FLoid imaging station (Thermo Fischer). Total number of cells and cells bearing two or more neurites were counted in 10 random fields and represented as percentage of cells in the graph [47] .
Kinase inhibition studies
Recombinant human IRE1a enzyme was obtained from SignalChem (Burlington, NC, USA) (#E31-11G). ADPGlo kinase assay (Promega) was performed as per the manufacturer's protocol to confirm the inhibitory mechanism of KFL. Briefly, 50 ng of enzyme was used with 10 or 100 lM of ATP with different concentrations of KFL in a white flat bottom 96-well plate. STS (Sigma Aldrich), a pan kinase inhibitor, was used as a positive control. The luminescence produced by the conversion of dephosphorylated ADP to ATP was measured using the luminometer (Berthold, Bad Wildbad, Germany).
In silico docking analysis
Studies to understand the mode of binding of KFL to IRE1a was carried out using AUTODOCK SUITE 4.0 (The Scripps Research Institute, La Jolla, CA, USA). Crystal structure of the human IRE1a bound with ADP (PDB ID: 3P23) was used as the target protein. Ligands were obtained from Pubchem as.sdf format and converted to.pdb using smiles translator. Polar hydrogen atoms were assigned for the macromolecule prior docking. Gasteiger charges for ligands and Kollman charges for the receptor molecule was added using AUTODOCK TOOLS 1.5.6 (The Scripps Research Institute). Throughout the study, the macromolecule was kept rigid with rotatable bonds assigned for the ligands. The grid center made on the macromolecule covering the entire surface of the protein acted as search space. AUTOGRID 4.0 was used to produce the map files of the flexible atoms and docking parameter file was generated using Lamarckian Genetic algorithm of AUTO- 
Statistical analysis
All data are presented as the standard error of mean (SEM) of at least three independent experiments. Statistical comparisons were performed using one-way/two-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test (GRAPHPAD PRISM, version 5.0, Graphpad Software, San Diego, CA, USA) and P-value of < 0.05 was considered statistically significant.
